Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 60Breast Neoplasms 54Ovarian Neoplasms 35Triple Negative Breast Neoplasms 28Lung Neoplasms 25Endometrial Neoplasms 25Fallopian Tube Neoplasms 24Neoplasm Metastasis 22Parkinson Disease 4, Autosomal Dominant Lewy Body 20Squamous Cell Carcinoma of Head and Neck 19Neoplasms 15Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 12Carcinoma, Ovarian Epithelial 10Stomach Neoplasms 9Head and Neck Neoplasms 9Carcinoma 9Colorectal Neoplasms 8Adenocarcinoma Of Esophagus 7Adenocarcinoma 7Peritoneal Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Respiratory Tract Neoplasms 3Recurrence 3

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Paclitaxel × 90 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡